We are live on ! Find out more
NC

Nexthera Capital Portfolio holdings

AUM $120M
1-Year Est. Return 10.01%
This Fund
S&P 500
This Quarter Est. Return
+5.16%
1 Year Est. Return
+10.01%
3 Year Est. Return
+160.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$230M
AUM Growth
+$33.5M
Cap. Flow
+$27.2M
Cap. Flow %
11.87%
Top 10 Hldgs %
55.53%
Holding
52
New
16
Increased
8
Reduced
12
Closed
11

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$9.17M
2
IPXL
Impax Laboratories, Inc.
IPXL
+$8.28M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$6.71M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$6.21M
5
FLXN
Flexion Therapeutics, Inc.
FLXN
+$4.8M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$14.5M
2
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
+$3.02M
3
CELG
Celgene Corp
CELG
+$2.56M
4
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
+$2.21M
5
TVRD
Tvardi Therapeutics
TVRD
+$2.11M

Sector Composition

Rank Sector Weight
1 Healthcare 70.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SIOX
51
CALL
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
– –
-12,500
Closed -$1.49M
TIG
52
DELISTED
TiGenix American Depositary Shares
TIG
– –
-92,203
Closed -$1.44M
1 2
3

Similar funds

KAM
Kavi Asset Management New York $121M AUM 7.54% 1-Year Est. Return
VCP
Vernier Capital Partners New York $132M AUM 20.75% 1-Year Est. Return
PFC
Personal Financial Consultants Lafayette, California $133M AUM 5.06% 1-Year Est. Return
FCA
Florence Capital Advisors New York $105M AUM
TA
TMD & Associates Scottsdale, Arizona $146M AUM 1.29% 1-Year Est. Return
EBIM
Eagle Boston Investment Management Boston, Massachusetts $87.3M AUM 4.18% 1-Year Est. Return
BCM
BBT Capital Management Fort Worth, Texas $85.5M AUM 11.09% 1-Year Est. Return
ACP
ArcLight Capital Partners Boston, Massachusetts $83.2M AUM 32.11% 1-Year Est. Return

Nexthera Capital's Q2 2017 Portfolio in Review

As of Q2 2017, Nexthera Capital held 52 positions worth $230M, up 17% from $196M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Nexthera Capital deployed $27.2M of net new capital in Q2 2017, opening 16 new positions and adding to 8 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 100,800 shares worth $9.15M.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 70% a quarter earlier.

On the sell side, the largest reduction was Pfizer, an estimated $14.5M trimmed.

  • Nexthera Capital's largest Q2 2017 buy was BioMarin Pharmaceuticals: 100,800 shares worth $9.15M.
  • Nexthera Capital added most to Aclaris Therapeutics in Q2 2017, an estimated $6.21M increase.
  • Nexthera Capital's biggest Q2 2017 reduction was Pfizer, cutting an estimated $14.5M.
  • Nexthera Capital fully exited Eiger BioPharmaceuticals, Inc. in Q2 2017, selling an estimated $3.02M.
  • Nexthera Capital's ten largest holdings make up 56% of its $230M portfolio in Q2 2017.
  • Nexthera Capital opened 16 new positions and closed 11 in Q2 2017.
  • Nexthera Capital's portfolio value rose 17% quarter-over-quarter to $230M.

Based on Nexthera Capital's 13F filing for Q2 2017, filed 14 Aug 2017.